Nuvalent (NUVL) investor relations material

Executive summary

• Advanced lead oncology programs zidesamtinib (ROS1+ NSCLC) and neladalkib (ALK+ NSCLC) to NDA stage, with NDA for zidesamtinib accepted by FDA and neladalkib submitted in April 2026.

• Building commercial infrastructure for potential US launch of zidesamtinib, pending FDA approval.

• No products approved or revenue generated to date; significant investments in R&D and commercialization preparation.

• Strengthened leadership team with key internal promotions in technology operations and medical affairs.

Financial highlights

• Net loss of $109.3 million for Q1 2026, compared to $84.6 million in Q1 2025.

• Operating expenses rose to $119.4 million (Q1 2026) from $94.8 million (Q1 2025), driven by increased R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $1.3 billion as of March 31, 2026.

• Working capital stood at $1.3 billion, with total assets of $1.37 billion and total liabilities of $156.8 million as of March 31, 2026.

• Accumulated deficit reached $1.1 billion as of March 31, 2026.

Outlook and guidance

• Existing cash resources expected to fund operations into 2029, but may not cover all candidates through regulatory approval.

• Anticipates FDA decision on zidesamtinib by September 18, 2026, and plans for label expansion submission in the second half of 2026.

• Anticipates continued significant net losses as R&D and commercialization activities expand.

• Plans to disclose a new development candidate by year-end 2026.